Investigation Report on China’s Atorvastatin Market 2021-2025

$2,600$3,900

In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of the hospital, the sales value of Atorvastatin in the Chinese market in 2020 dropped to CNY825 million, and the CAGR is about -20.30% from 2016 to 2020.

Clear

Description

Atorvastatin is a statin drug, which is used to lower blood cholesterol levels. This common drug is mainly used to treat high cholesterol, hyperlipidemia, and coronary heart disease. The original drug Atorvastatin was developed by Pfizer Pharmaceuticals under the trade name LIPITOR. According to CRI’s analysis, Lipitor entered the Chinese market in 1999, and then some Chinese local companies’ generic drugs were successively listed. Pfizer Pharmaceuticals still accounts for the most market share in China by 2020.

According to CRI’s market research, the sales value of Atorvastatin in the Chinese market increased from 2016 to 2018. In 2019, due to being included in the Chinese government’s “4+7” policy for drug centralized procurement, the price of the drug fell sharply, resulting in a year-on-year decrease of 18.33% in its sales value. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of the hospital, the sales value of Atorvastatin in the Chinese market in 2020 dropped to CNY825 million, and the CAGR is about -20.30% from 2016 to 2020.

CRI expects that with the effective relief of COVID-19, the sales value of Atorvastatin in the Chinese market will have a restorative growth from 2021 to 2025. In addition, the seventh census showed that as of the end of 2020, the total population of China was 1,411.78 million, and the population of 60 years and over was 264.02 million, accounting for 18.70% of the total population. It is expected that the elderly population in China will show an increasing trend. The proportion of the elderly population will continue to rise, and the incidence of cardiovascular diseases will continue to rise accordingly. In addition, as the pace of life of Chinese residents accelerates, unhealthy lifestyles increase the risk of blood lipid diseases and expand the market for Atorvastatin. Therefore, CRI predicts that sales value of Atorvastatin in the Chinese market will continue to grow from 2021 to 2025.

Additional information

Publisher

Date Published

Pages

Charts

Format

Table of Contents

1 Relevant Concepts of Atorvastatin

  • 1.1 Indications for Atorvastatin
  • 1.2 Development of Atorvastatin in China
  • 1.3 Governmental Approval of Atorvastatin in China
  • 1.4 The Impact of COVID-19 on Atorvastatin sales in China

 

2 Sales of Atorvastatin in China, 2016-2020

  • 2.1 Sales Value of Atorvastatin
  • 2.1.1 Overall Sales Value
  • 2.1.2 Sales Value by Regions
  • 2.2 Sales Volume of Atorvastatin
  • 2.2.1 Overall Sales Volume
  • 2.2.2 Sales Volume by Regions
  • 2.3 Sales of Atorvastatin by Dosage Form in China, 2016-2020
  • 2.3.1 Dispersible Tablets
  • 2.3.3 Tablets
  • 2.3.3 Capsules

 

3 Analysis of Major Atorvastatin Manufacturers in China, 2016-2020

  • 3.1 Analysis of Market Share of Major Atorvastatin Manufacturers
  • 3.1.1 Investigation on Market Share by Sales Value
  • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Pfizer Inc
  • 3.2.1 Enterprise Profile
  • 3.2.2 Sales of LIPITOR (Pfizer Inc’s Atorvastatin) in China
  • 3.3  Lepu Medical Technology Co., Ltd.
  • 3.3.1 Enterprise Profile
  • 3.3.2 Sales of Youliping (Lepu Medical Technology Co., Ltd. ’s Atorvastatin) in China
  • 3.4 Beijing Jialin Pharmaceutical Co., Ltd.
  • 3.4.1 Enterprise Profile
  • 3.4.2 Sales of Ale (Beijing Jialin Pharmaceutical Co., Ltd. ’s Atorvastatin) in China
  • 3.5 Qilu Pharmaceutical (Hainan) Co., Ltd.
  • 3.5.1 Enterprise Profile
  • 3.5.2 Sales of Meidaxin (Qilu Pharmaceutical (Hainan) Co., Ltd.’s Atorvastatin) in China
  • 3.6 Fujian Dawnrays Pharmaceutical Co., Ltd.
  • 3.6.1 Enterprise Profile
  • 3.6.2 Sales of Anweining (Fujian Dawnrays Pharmaceutical Co., Ltd.’s Atorvastatin) in China

 

4 Prices of Atorvastatin for Different Manufacturers in China, 2020-2021

  • 4.1 Pfizer Inc (LIPITOR)
  • 4.2 Lepu Medical Technology Co., Ltd.  (Youliping)
  • 4.3 Beijing Jialin Pharmaceutical Co., Ltd.  (Ale)
  • 4.4 Qilu Pharmaceutical (Hainan) Co., Ltd. (Meidaxin)
  • 4.5 Fujian Dawnrays Pharmaceutical Co., Ltd. (Anweining)

 

5 Prospect of Chinese Atorvastatin Market, 2021-2025

  • 5.1 Influential Factors of Chinese Atorvastatin Market Development
  • 5.1.1 The Impact of COVID-19 on Chinese Atorvastatin Market
  • 5.1.2 Market Drivers and Opportunities
  • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

 

List of Charts

  • Chart Patent Information About Atorvastatin Dispersible Tablets Registration in China
  • Chart Patent Information About Atorvastatin Tablets Registration in China
  • Chart Patent Information About Atorvastatin Capsules Registration in China
  • Chart Sales Value of Atorvastatin Dispersible Tablets over the World
  • Chart Sales Value of Atorvastatin Tablets over the World
  • Chart Sales Value of Atorvastatin Capsules over the World
  • Chart Sales Value of Atorvastatin Dispersible Tablets in China, 2016-2020
  • Chart Sales Value of Atorvastatin Tablets in China, 2016-2020
  • Chart Sales Value of Atorvastatin Capsules in China, 2016-2020
  • Chart Sales Value of Atorvastatin Dispersible Tablets in China by Regions, 2016-2020
  • Chart Sales Value of Atorvastatin Tablets in China by Regions, 2016-2020
  • Chart Sales Value of Atorvastatin Capsules in China by Regions, 2016-2020
  • Chart Sales Volume of Atorvastatin Dispersible Tablets in China, 2016-2020
  • Chart Sales Volume of Atorvastatin Tablets in China, 2016-2020
  • Chart Sales Volume of Atorvastatin Capsules in China, 2016-2020
  • Chart Sales Volume of Atorvastatin Dispersible Tablets in China by Regions, 2016-2020
  • Chart Sales Volume of Atorvastatin Tablets in China by Regions, 2016-2020
  • Chart Sales Volume of Atorvastatin Capsules in China by Regions, 2016-2020
  • Chart Market Share by Sales Value of Top Atorvastatin Dispersible Tablets Manufacturers in China, 2016-2020
  • Chart Market Share by Sales Value of Top Atorvastatin Tablets Manufacturers in China, 2016-2020
  • Chart Market Share by Sales Value of Top Atorvastatin Capsules Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of LIPITOR in China, 2016-2020
  • Chart Sales Value and Volume of Youliping in China, 2016-2020
  • Chart Sales Value and Volume of Ale in China, 2016-2020
  • Chart Sales Value and Volume of Meidaxin in China, 2016-2020
  • Chart Sales Value and Volume of Anweining in China, 2016-2020
  • Chart Referential Prices of LIPITOR in China by Regions, 2020-2021
  • Chart Referential Prices of Youliping in China by Regions, 2020-2021
  • Chart Referential Prices of Ale in China by Regions, 2020-2021
  • Chart Referential Prices of Meidaxin in China by Regions, 2020-2021
  • Chart Referential Prices of Anweining in China by Regions, 2020-2021
  • Chart Forecast on Sales Value of Atorvastatin Dispersible Tablets in China, 2021-2025
  • Chart Forecast on Sales Value of Atorvastatin Tablets in China, 2021-2025
  • Chart Forecast on Sales Value of Atorvastatin Capsules in China, 2021-2025
  • Chart Forecast on Sales Volume of Atorvastatin Dispersible Tablets in China, 2021-2025
  • Chart Forecast on Sales Volume of Atorvastatin Tablets in China, 2021-2025
  • Chart Forecast on Sales Volume of Atorvastatin Capsules in China, 2021-2025
RSS
Follow by Email